Antag Therapeutics

Antag Therapeutics is a clinical-stage biopharmaceutical company developing GIP receptor antagonists to treat obesity, type 2 diabetes, and metabolic disorders. Its lead candidate, AT-7687, is a peptide designed to block biological pathways contributing to fat storage and insulin resistance rather than suppressing appetite through incretin stimulation. The company targets patients seeking long-term weight management and metabolic health through both monotherapy and combination treatment options.